Arrowhead Pharmaceuticals, INC.
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersPasadena, CA
US patents93
SAM.gov UEIU5V3TTMXBJG4
CAGE code17B71
Incorporated inDE
LEI549300O3CSB8T7OZ3D66
Supplier designations
For Profit Organization
Self-certified by the company in its SAM.gov registration
Patents
93 US patents granted 2016–2025, 39 of them in the five years to SEP 2025.
Pharmaceuticals 83Biotechnology 7Organic fine chemistry 2
- RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of useUS 12,378,558 · granted AUG 5, 2025
- RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)US 12,365,899 · granted JUL 22, 2025
- RNAi agents for inhibiting expression of mucin 5AC (MUC5AC), compositions thereof, and methods of useUS 12,365,897 · granted JUL 22, 2025
- RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of useUS 12,221,610 · granted FEB 11, 2025
- Compositions and methods for inhibiting gene expression of alpha-1 antitrypsinUS 12,188,017 · granted JAN 7, 2025
Newest 5 shown · Granted to Arrowhead Pharmaceuticals, Inc. · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Arrowhead Pharmaceuticals, INC. | Pasadena | CA | — | LIKELY ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.